Ireland
--:--IST
Starting soon Not applicable

Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndrome ) with Dynamic Hyperinflation. EDIN-IDIN.

NCT06713486 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2024-12-01
Last updated
2024-12-03

Condition(s) studied

Pulmonary Disease, Chronic Obstructive

Investigational drug(s) / intervention(s)

Fixed pressure obtained in the polysomnography for 28 daysDynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode

Fixed pressure obtained in the polysomnography for 28 days: home nocturnal therapy either at the fixed pressure obtained in the polysomnography for 28 days

Dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode: dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode (program B) for 28 days, using the apnea threshold obtained in the titration as the maximum EPAP pressure and adjusting the support pressure for inferred Vt to 8 ml/kg of ideal body weight. After the first 28 days, a polysomnography will be performed under therapy with the device, and the next morning, cycle ergometry will be conducted.

Study summary

The combination of COPD and obstructive sleep apnea (OSA) can lead to undesirable interactions with the treatment approach. The investigators know that continuous positive airway pressure (CPAP) can increase dynamic hyperinflation in COPD patients, and in mechanical ventilation, the increase in PEEP can worsen dynamic hyperinflation. On the other hand, the team know that the severity of COPD obstruction and hyperinflation alter sleep efficiency, with periods of wakefulness during sleep, and during these periods, the patient would not have upper airway obstruction, which could affect the therapy they are receiving in CPAP mode for OSA. Moreover, it was observed that with greater hyperinflation, the rate of obstructive events decreases, dynamically affecting the ventilatory situation with upper airway resistance. Recent studies have determined the safety and efficacy of auto-adjusting systems in the treatment of overlap syndrome, which could be more adaptable to the changing pulmonary mechanics of these patients. Aerobic capacity is a good predictor to the health status in these patients and the investigators know it is reduced in patients with AOS, where CPAP treatment according to studies improves the peak VO2. Therefore, the objective is to compare a ventilation system with fixed pressures established through polysomnography in patients with overlap syndrome and dynamic hyperinflation to a dynamic ventilation system using the fixed pressure limits typically established, based on their impact on the aerobic capacity (peak VO2) of these patients after 1 month of treatment.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Stability of at least 4 weeks without hospital admission. * Previously presented PCO2 \> 52. * Age between 50 and 80 years. * Agree to participate in the study and sign the informed consent. * Both sexes. Exclusion Criteria: * Refusal to participate in the study. * Uncontrolled structural or coronary heart disease (no changes in medication in the last 15 days). * LVEF \< 45%. * Central sleep apnea syndrome (≥ 50% central events). * Uncontrolled pulmonary hypertension. * Inability to perform the tests. * Having had an exacerbation 4 weeks prior. * Severe psychiatric illness. * Cognitive impairment. * Not speaking Spanish. * Illiteracy. * Active smoker (or \< 6 months since quitting smoking).

Primary outcome measure(s)

  • Peak VO2 — 0,29 and 57 days.
    Peak VO2 as the primary variable obtained from cycle ergometry.

Trial sites (1)

FacilityCityRegionStatus
Servicio de Neumología. Hospital Universitario Virgen de la Arrixaca. Murcia Murcia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06713486 on ClinicalTrials.gov ↗ ← All trials in Spain